Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases

Autor: Divya Natesan, MD, David J. Carpenter, MD, Will Giles, PhD, Taofik Oyekunle, MS, Donna Niedzwiecki, PhD, Zachary J. Reitman, MD, PhD, John P. Kirkpatrick, MD, PhD, Scott R. Floyd, MD, PhD

Publikováno v: Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101211- (2023)

Purpose: Existing brain metastasis prognostic models do not identify patients at risk of very poor survival after radiation therapy (RT). Identifying patient and disease risk factors for 30-day mortality (30-DM) after RT may help identify patients wh

Externí odkaz: https://doaj.org/article/38ff35436fd84befa15f760f5d20b9bb

Optimizing Management of the Central Nervous System in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Autor: Pranalee Patel, BS, Mairead Dillon, BS, Donna Niedzwiecki, PhD, Mitchell E. Horwitz, MD, Chris R. Kelsey, MD

Publikováno v: Advances in Radiation Oncology, Vol 8, Iss 2, Pp 101082- (2023)

Purpose: To evaluate clinical outcomes and patterns of failure, specifically in regards to the central nervous system (CNS), in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) usin

Externí odkaz: https://doaj.org/article/e02b9be253cb4d15a9e8988bd8b99bcc

Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer

Autor: Divya Natesan, MD, David J. Carpenter, MD, MHS, Warren Floyd, BS, Taofik Oyekunle, MS, Donna Niedzwiecki, PhD, Laura Waters, NP, Devon Godfrey, PhD, Michael J. Moravan, MD, PhD, William Robert Lee, MD, Joseph K. Salama, MD

Publikováno v: Advances in Radiation Oncology, Vol 7, Iss 2, Pp 100805- (2022)

Purpose: To evaluate the effect of prostate volume on outcomes after moderately hypofractionated radiation therapy (mHFRT) for prostate cancer. Methods and Materials: Prostate cancer patients treated with mHFRT at a Veteran's Affairs Medical Center f

Externí odkaz: https://doaj.org/article/b91b418654384d83b03908e41b47c1b3

Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions

Autor: Jeremy G. Price, MD, PhD, Donna Niedzwiecki, PhD, Taofik Oyekunle, MS, Murat O. Arcasoy, MD, Colin E. Champ, MD, Chris R. Kelsey, MD, Joseph K. Salama, MD, Michael J. Moravan, MD, PhD

Publikováno v: Advances in Radiation Oncology, Vol 6, Iss 4, Pp 100729- (2021)

Background: Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12

Externí odkaz: https://doaj.org/article/ef4da5ce77854187842f6d08bac961d3

Reply to S. Sorscher.

Autor: Innocenti F; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Ou FS; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Qu X; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Zemla T; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Niedzwiecki D; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Tam R; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Mahajan S; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Goldberg RM; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Bertagnolli MM; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Blanke CD; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Sanoff H; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Atkins J; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Polite B; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Venook AP; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Lenz HJ; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA., Kabbarah O; Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Sep 01; Vol. 37 (25), pp. 2291-2293. Date of Electronic Publication: 2019 Jul 03.